New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
11:40 EDTWWE, JCP, QIWI, DANG, ITMN, CLVS, ECYT, DTV, NSR, PWRDOptions with decreasing implied volatility
Options with decreasing implied volatility: CLVS JCP NSR ITMN WWE DTV DANG PWRD ECYT QIWI
News For CLVS;JCP;NSR;ITMN;WWE;DTV;DANG;PWRD;ECYT;QIWI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
17:30 EDTQIWIQIWI files to sell 1.68M American Depositary Shares for holders
Subscribe for More Information
16:24 EDTPWRDMan Group reports 5.31% stake in Perfect World
10:38 EDTCLVSFly Watch: Biotech sector events to watch for this summer
Three key events in the biotech sector are slated to occur this summer, Mizuho Securities previewed in a note to investors today. Namely, data from Clovis Oncology's (CLVS) lung cancer treatment is expected to be released, interim data for Verastem's (VSTM) cancer treatment could be unveiled and the PDUFA date for Tesaro's (TSO) rolapitant drug for chemotherapy-induced nausea and vomiting will occur. A PDUFA date is the day on which the FDA is expected to decide whether to approve a drug. WHAT'S NEW: Data for Clovis' rociletinib lung cancer treatment is expected by the firm to be released September 6-9, Mizuho analyst Peter Lawson wrote. Favorable data could result in the the drug more quickly becoming the first treatment option after it hits the market, the analyst stated. Interim data for Verastem's cancer treatment product, defactinib, will have one of three outcomes, Lawson forecast: additional patients will be enrolled in the study, the study will be terminated due to poor results or the patients in the study with low levels of a tumor suppressor gene product called Merlin will be enriched for Merlin. According to Lawson, expectations heading into the trial are low, and the most likely outcome is that the Merlin enrichment scenario will occur. If this scenario does occur, Verastem's stock will probably temporarily fall, potentially creating a better entry point, Lawson believes. The PDUFA date for Tesaro's rolapitant drug is September 5, the analyst stated. The analyst kept a $103 price target and Buy rating on Clovis, a $67 price target and Buy rating on Tesaro and a $21 price target and Buy rating on Verastem. PRICE ACTION In early trading, Clovis fell 2.2% to $83.98, Verastem retreated 2.3% to $6.96 and Tesaro dropped 1.7% to $55.80.
July 1, 2015
16:07 EDTCLVSClovis initiates rolling NDA submission to FDA for Rociletinib
Subscribe for More Information
15:23 EDTDTVDISH's Ergen awaits AT&T-DirecTV approval before more T-Mobile talks, FBN says
Subscribe for More Information
13:57 EDTDTVAT&T-DirecTV deal set to be cleared by U.S. antitrust officials, Bloomberg says
AT&Tís (T) proposed $48.5B deal to buy DirecTV (DTV) is slated to be cleared by U.S. antitrust officials without any conditions, Bloomberg reports, citing a personal familiar with the deliberations by the Justice Department. The merger still requires approval from the FCC, which may demand concessions such as following net neutrality rules, the report says. Reference Link
June 30, 2015
18:11 EDTDTVAT&T, DirecTV merger may get U.S. approval next week, Reuters says
Subscribe for More Information
15:20 EDTJCPMoody's raises J.C. Penney liquidity rating to SGL-1 from SGL-2
Moody's Investors Service revised J.C. Penney's rating outlook to positive from stable. Moody's also affirmed the company's Caa1 Corporate Family Rating, and raised the company's Speculative Grade Liquidity rating to SGL-1 from SGL-2. "The rating outlook revision to positive from stable reflects Moody's view that JC Penney's operating performance has shown signs of improvement as a result of better merchandising, cost controls, and integration of its online business" said Moody's Vice President Scott Tuhy. He added, "we have seen positive momentum building for the company to achieve $700M to $800M of adjusted EBITDA, a level in which earnings would fully cover cash flow and interest". The upgrade in the Speculative Grade Liquidity rating primarily reflects the company's improved operating performance as we expect free cash flow to be near break-even levels and the company's meaningful cash balances are sufficient to cover expected seasonal working capital needs.
June 29, 2015
17:25 EDTDTVAT&T, DirecTV elect to further extend merger termination date
Subscribe for More Information
15:32 EDTDTVDoubtful that FCC votes on AT&T, DirecTV deal this week, CTFN says
Sources said it is looking "increasingly doubtful" that the FCC will vote this week on the proposed merger between AT&T (T) and DirecTV (DTV), according to CTFinancialNews. Reference Link
June 24, 2015
10:26 EDTJCPStocks with call strike movement; TWTR JCP
Twitter (TWTR) December 40 call option implied volatility increased 1% to 44, J.C. Penney (JCP) November 20 call option implied volatility decreased 5% to 42 according to IVolatility.
June 23, 2015
05:41 EDTDTVAT&T upgraded to Buy from Neutral at UBS
UBS analyst John Hodulik upgraded AT&T (T) to Buy citing an attractive valuation at current share levels. Hodulik expects the phone giant's core domestic wireless business to show "meaningful improvement" in Q2. He also thinks financial benefits from the DirecTV (DTV) acquisition are being underappreciated by the market. Hodulik raised his price target for AT&T shares to $42 from $34. The stock was also upgraded this morning by Barclays analyst Amir Rozwadowski. AT&T shares closed yesterday up 5c to $35.04.
05:35 EDTDTVAT&T upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Amir Rozwadowski upgraded AT&T (T) to Overweight saying earnings estimates should move higher following the close of the DirecTV (DTV) acquisition. After visiting AT&T's headquarters, Rozwadowski believes synergies from the deal are "too material to ignore." He raised his price target for AT&T shares to $39 from $34. The stock closed yesterday up 5c to $35.04.
June 22, 2015
09:52 EDTDTVKimberly-Clark names DirecTV CEO Michael White to board of directors
Subscribe for More Information
08:03 EDTCLVSClovis names Dr. Lindsey Rolfe as Chief Medical Officer
Clovis Oncology announced that Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, has been named Chief Medical Officer and EVP of Clinical and Preclinical Development and Pharmacovigilance, to become effective in early August. Dr. Rolfe succeeds Dr. Andrew Allen, who will be stepping down from his role at Clovis at that time to create a new immuno-oncology focused biotechnology company and serve as its CEO. Dr. Rolfe joined Clovis in early 2010 and oversees rociletinib and rucaparib development in her current role as SVP of Clinical Development. As Chief Medical Officer at Clovis, Dr. Rolfe will be responsible for clinical development, preclinical development, clinical operations and pharmacovigilance and will also serve on the companyís executive committee.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use